ClinicalTrials.Veeva

Menu

Effect of rIL-21 on Metastases in Lymph Nodes in Melanoma Skin Cancer

Novo Nordisk logo

Novo Nordisk

Status and phase

Terminated
Phase 2

Conditions

Malignant Melanoma
Cancer

Treatments

Drug: recombinant interleukin-21

Study type

Interventional

Funder types

Industry

Identifiers

NCT00601861
NN028-1801
2006-005350-79 (EudraCT Number)

Details and patient eligibility

About

The trial is conducted in Europe. This trial aims for a comparison of the pathology in lymph nodes before and after the effect of recombinant interleukin-21 in patients with stage III melanoma

Full description

The decision to discontinue the NN028-1801 trial is not due to any safety concerns. The trial was terminated as a result of a strategic decision by the sponsoring company.

Enrollment

1 patient

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Stage III melanoma
  • ECOG performance status 0-1

Exclusion criteria

  • Signs of stage IV melanoma
  • Safety variables

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Single Group Assignment

Masking

None (Open label)

1 participants in 1 patient group

A
Experimental group
Treatment:
Drug: recombinant interleukin-21

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems